Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma

MeSH terms

• Aged
• Aged, 80 and over
• Antibodies, Monoclonal / pharmacology
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Combined Modality Therapy
• Cyclophosphamide / administration & dosage
• Disease-Free Survival
• Doxorubicin / administration & dosage
• Doxorubicin / analogs & derivatives
• Drug Evaluation
• Female
• Genes, bcl-2
• Humans
• Immunotherapy*
• Lymphoma, Large B-Cell, Diffuse / classification
• Lymphoma, Large B-Cell, Diffuse / drug therapy*
• Lymphoma, Large B-Cell, Diffuse / genetics
• Lymphoma, Large B-Cell, Diffuse / mortality
• Lymphoma, Large B-Cell, Diffuse / pathology
• Male
• Middle Aged
• NF-kappa B / antagonists & inhibitors
• Prednisolone / administration & dosage
• Retrospective Studies
• Rituximab
• Survival Analysis
• Treatment Outcome
• Vincristine / administration & dosage